Immune Checkpoint Blockade in Melanoma - Earlier is Better?

Acta Med Litu · 2024 · PMC11227685 · PMID 38978863

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among those treated with targeted therapy, individuals achieving pCR showed a trend toward better Recurrence-Free Survival (RFS) at 2 years (60%) compared to those with a partial response (PR) (44%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.